Jpmorgan Chase & CO Nrx Pharmaceuticals, Inc. Transaction History

Jpmorgan Chase & CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$0.29 - $0.7 $4,732 - $11,424	-16,320 Reduced 97.07%	492 $0
Q4 2023 Feb 12, 2024	BUY	$0.26 - $0.47 $4,282 - $7,742	16,473 Added 4859.29%	16,812 $7,000
Q4 2022 Feb 13, 2023	SELL	$0.79 - $9.19 $694,111 - $8.07 Million	-878,622 Reduced 99.96%	339 $0
Q3 2022 Nov 14, 2022	BUY	$0.2 - $8.07 $175,401 - $7.08 Million	877,007 Added 44882.65%	878,961 $650,000
Q2 2022 Aug 11, 2022	SELL	$0.51 - $2.42 $2,548 - $12,095	-4,998 Reduced 71.89%	1,954 $1,000
Q1 2022 May 11, 2022	BUY	$2.45 - $5.04 $4,331 - $8,910	1,768 Added 34.1%	6,952 $17,000
Q4 2021 Feb 10, 2022	BUY	$4.5 - $11.91 $22,374 - $59,216	4,972 Added 2345.28%	5,184 $25,000
Q3 2021 Nov 12, 2021	BUY	$8.52 - $24.77 $1,806 - $5,251	212 New	212 $2,000

17.4K

Ticker NRXP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,641,296
Market Cap $111M
Description
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-10...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.